Growing Retinal Disorder Incidence Propels Macular Degeneration Treatment Market: A Key Catalyst Accelerating Macular Degeneration Treatment Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Macular Degeneration Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size for the treatment of macular degeneration has seen substantial growth recently. The projections suggest an increase from $11.05 billion in 2024 to $12.42 billion in 2025, indicating a compound annual growth rate (CAGR) of 12.4%. Factors contributing to this growth in the past include an increasing elderly population, modifications in lifestyle, limited therapeutic alternatives, higher consciousness and advancements in healthcare infrastructure.

How Will the Macular Degeneration Treatment Market Size Evolve and Grow by 2029?
The market for macular degeneration treatments is predicted to experience rapid expansion in the coming years, reaching an estimated worth of $19.06 billion in 2029 with a compound annual growth rate (CAGR) of 11.3%. This projected growth during the forecast period is due to advancements in research, increased spending on healthcare, higher incidence rates, bespoke medicine strategies, and worldwide initiatives for vision health. Key trends in the forecast period encompass an emphasis on neuroprotection and regeneration therapies, development of telemedicine and remote surveillance, tailored medicinal approaches, exploration into stem cell therapies, and patient-centric programs for awareness and education.

View the full report here:
https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

What Drivers Are Propelling the Growth of Macular Degeneration Treatment Market Forward?
The growing issue of retinal disorders is anticipated to stimulate the expansion of the macular degeneration treatment market. These disorders can harm crucial tissue and disrupt the way people interpret visual data, leading to vision loss or distortion. For example, the American Academy of Ophthalmology predicts that by 2050, around 7.32 million individuals in the United States will suffer from primary open-angle glaucoma, a collective term for various eye disorders. The highest prevalence rates will be amongst populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%), with Hispanic males being the largest demographic. Thus, the escalating challenge of retinal disorders is spurring the growth of the macular degeneration treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

Which Emerging Trends Are Transforming the Macular Degeneration Treatment Market in 2025?
Leading firms in the macular degeneration treatment market are concentrating their efforts on creating biosimilars to treat age-related macular degeneration (AMD), aiming to expand access to effective therapies. Biosimilars are biologic medical products that closely resemble an already approved reference product and exhibit no noticeable differences in purity, safety, or efficacy. For example, in May 2024, India's Biocon Biologics Ltd and South Korea's Samsung Bioepis Co. Ltd earned FDA approvals for Yesafili and Opuviz, two new biosimilars. These biosimilars counteract the vascular endothelial growth factor (VEGF), which triggers abnormal blood vessel growth in the eye, thereby preventing vision loss related to AMD and diabetic retinopathy. The FDA approval was based on comparative studies demonstrating that Yesafili and Opuviz were just as safe and efficient as Eylea, following rigorous analyses of the biosimilars' pharmacokinetics and immunogenicity.

What Are the Key Segments in the Macular Degeneration Treatment Market?
The macular degeneration treatment market covered in this report is segmented -

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD
2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals
3) By Route of Administration: Oral, Injectable, Other Route of Administration
4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Subsegments:
1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments
2) By Intermediate AMD: Anti-VEGF Injections, Photodynamic Therapy
3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=5799&type=smp

Who Are the Key Players Shaping the Macular Degeneration Treatment Market's Competitive Landscape?
Major companies operating in the macular degeneration treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.

What Geographic Markets Are Powering Growth in the Macular Degeneration Treatment Market?
North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment Market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5799

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.